Fetuin-A and arterial stiffness in patients with normal kidney function

Regulatory Peptides

Volumn 154, Issue 1-3, 2009, Pages 39-43

  Roos, Marcel ^a   Richart, Tom ^b,c   Kouznetsova, Tatiana ^b   von Eynatten, Maximilian ^a   Lutz, Jens ^a   Heemann, Uwe ^a   Baumann, Marcus ^a   Staessen, Jan A ^b,c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Arterial stiffness; Calcium metabolism; Fetuin A; Pulse wave velocity; Single nucleotide polymorphism

Indexed keywords

CALCIUM; FETUIN A; SERINE; THREONINE;

ADULT; AGED; ARTERIAL STIFFNESS; ARTERY COMPLIANCE; ARTICLE; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENE; HUMAN; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSE WAVE;

ADULT; ALLELES; ALPHA-FETOPROTEINS; AORTA; BELGIUM; BLOOD FLOW VELOCITY; CALCINOSIS; CAROTID ARTERY, COMMON; CREATININE; FEMALE; GENE FREQUENCY; HETEROZYGOTE; HUMANS; KIDNEY; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PULSATILE FLOW; SEX FACTORS; VASCULAR RESISTANCE;

EID: 63049108844     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2008.12.001     Document Type: Article

References (34)

1. Hansen T.W., Staessen J.A., Torp-Pedersen C., Rasmussen S., Thijs L., Ibsen H., and Jeppesen J. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 113 (Feb. 7 2006) 664-670
2. London G.M., Marchais S.J., Guerin A.P., Metivier F., Adda H., and Pannier B. Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients. Kidney Int Suppl (2003) S88-S93
3. Schinke T., Amendt C., Trindl A., Poschke O., Muller-Esterl W., and Jahnen-Dechent W. The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. J Biol Chem 271 (1996) 20789-20796
4. Schafer C., Heiss A., Schwarz A., Westenfeld R., Ketteler M., Floege J., Muller-Esterl W., Schinke T., and Jahnen-Dechent W. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 112 3 (Aug 2003) 357-366
5. Ketteler M., Bongartz P., Westenfeld R., Wildberger J.E., Mahnken A.H., Bohm R., Metzger T., Wanner C., Jahnen-Dechent W., and Floege J. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 361 (2003) 827-833
6. Keeley K.W., and Sitarz E.E. Identification and quantitation of alpha 2-HS-glycoprotein in the mineralized matrix of calcified plaques of atherosclerotic human aorta. Atherosclerosis 55 (1985) 63-69
7. Lehtinen A.B., Burdon K.P., Lewis J.P., Langefeld C.D., Ziegler J.T., Rich S.S., Register T.C., Carr J.J., Freedman B.I., and Bowden D.W. Association of alpha2-Heremans-Schmid glycoprotein polymorphisms with subclinical atherosclerosis. J Clin Endocrinol Metab 92 1 (Jan 2007) 345-352 [Electronic publication 2006 Oct 24]
8. Stenvinkel P., Wang K., Qureshi A.R., Axelsson J., Pecoits-Filho R., Gao P., Barany P., Lindholm B., Jogestrand T., Heimburger O., Holmes C., Schalling M., and Nordfors L. Low fetuin-A levels are associated with cardiovascular death: impact of variations of gene encoding fetuin. Kidney Int 67 (2005) 2283-2392
9. Hermans M.M., Brandenburg V., Ketteler M., Kooman J.P., van der Sande F.M., Gladziwa U., Rensma P.L., Bartelet K., Konings C.J., Hoeks A.P., Floege J., and Leunissen K.M. Study on the relationship of serum fetuin-A concentration with aortic stiffness in patients on dialysis. Nephrol Dial Transplant 21 5 (May 2006) 1293-1299 [Electronic publication 2006 Jan 5]
10. Shroff R.C., Shah V., Hiorns M.P., Schoppet M., Hofbauer L.C., Hawa G., Schurgers L.J., Singhal A., Merryweather I., Brogan P., Shanahan C., Deanfield J., and Rees L. The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not Matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrol Dial Transplant (May 9 2008) [Electronic publication ahead of print]
11. Balkestein E.J., Staessen J.A., Wang J.G., van Der Heijden-Spek J.J., Van Bortel L.M., Barlassina C., Bianchi G., Brand E., Herrmann S.M., and Struijker-Boudier H.A. Carotid and femoral artery stiffness in relation to three candidate genes in a white population. Hypertension 38 5 (Nov 2001) 1190-1197
12. Sattar N., Gaw A., Scherbakova O., Ford I., O'Reilly D.S., Haffner S.M., Isles C., Macfarlane P.W., Packard C.J., Cobbe S.M., and Shepherd J. Metabolic syndrome with and without C-protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary prevention study. Circulation 108 (2003) 414-419
13. Ridker P.M., Buring J.E., Cook N.R., and Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow up of 14719 initially healthy American women. Circulation 107 (2003) 391-397
14. Gold E.B., Bromberger J., Crawford S., Samuels S., Greendale G.A., Harlow S.D., and Skurnick J. Factors associated with age at natural menopause in a multiethnic sample of midlife women. Am J Epidemiol 153 9 (May 1 2001) 865-874
15. Kuznetsova T., Staessen J.A., Kawecka-Jaszcz K., Babeanu S., Casiglia E., Filipovsky J., Nachev C., Nikitin Y., Peleska J., and O'Brien E. Quality control of the blood pressure phenotype in the European Project on Genes in Hypertension. Blood Press Monit 7 (2002) 215-224
16. Van Bortel L.M., Balkestein E.J., van der Heijden-Spek J.J., Vanmolkot F.H., Staessen J.A., Kragten J.A., Vredeveld J.W., Safar M.E., Struijker Boudier H.A., and Hoeks A.P. Non-invasive assessment of local arterial pulse pressure: comparison of applanation tonometry and echo-tracking. J Hypertens 19 (2001) 1037-1044
17. Hoeks A.P.G., and Reneman R.S. Biophysical principles of vascular diagnosis. J Clin Ultrasound 23 (1995) 71-79
18. Schedel M., Carr D., Klopp N., Woitsch B., Illig T., Stachel D., Schmid I., Fritzsch C., Weiland S.K., Von Mutius E., and Kabesch M. A signal transducer and activator of transcription 6 haplotype influences the regulation of serum IgE levels. J Allergy Clin Immunol 114 (2004) 1100-1105
19. Laurent S., Boutouyrie P., and Lacolley P. Structural and genetic bases of arterial stiffness. Hypertension 45 6 (Jun 2005) 1050-1055 [Electronic publication 2005 Apr 25, Review]
20. Lakatta E.G., and Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part I: aging arteries: a "set up" for vascular disease. Circulation 107 1 (Jan 7 2003) 139-146 [Review, No abstract available]
21. Ruiz-Ortega M., Rodríguez-Vita J., Sanchez-Lopez E., Carvajal G., and Egido J. TGF-beta signaling in vascular fibrosis. Cardiovasc Res 74 2 (May 1 2007) 196-206 [Electronic publication 2007 Feb 12, Review]
22. Demetriou M., Binkert C., Sukhu B., Tenenbaum H.C., and Dennis J.W. Fetuin/alpha2-HS glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine antagonist. J Biol Chem 271 (1996) 12755-12761
23. Verma.Gandhu M., Peterson M.R., and Peterson T.C. Effect of fetuin, a TGF-beta antagonist and pentoxifylline, a cytokine antagonist on hepatic stellate cell function and fibrotic parameters in fibrosis. Eur J Pharmacol 572 2-3 (Oct 31 2007) 220-227
24. Merx M.W., Schäfer C., Westenfeld R., Brandenburg V., Hidajat S., Weber C., Ketteler M., and Jahnen-Dechent W. Myocardial stiffness, cardiac remodeling, and diastolic dysfunction in calcification-prone fetuin-A-deficient mice. J Am Soc Nephrol 16 11 (Nov 2005) 3357-3364 [Electronic publication 2005 Sep 21]
25. Reynolds J.L., Skepper J.N., McNair R., Kasama T., Gupta K., Weissberg P.L., Jahnen-Dechent W., and Shanahan C.M. Multifunctional roles for serum protein fetuin-A in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol 16 (2005) 2920-2930
26. Coen G., Ballanti P., Balducci A., Grandi F., Manni M., Mantella D., Pierantozzi A., Ruggeri M., Sardella D., Sorbo G., and Bonucci E. Renal osteodystrophy: alpha-Heremans Schmid glycoprotein/fetuin-A, matrix GLA protein serum levels, and bone histomorphometry. Am J Kidney Dis 48 1 (Jul 2006) 106-113
27. Ix J.H., Shlipak M.G., Brandenburg V.M., Ali S., Ketteler M., and Whooley M.A. Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation 113 14 (Apr 11 2006) 1760-1767 [Electronic publication 2006 Mar 27]
28. Stefan N., Fritsche A., Weikert C., Boeing H., Jost H.G., Häring H.U., and Schulze M.B. Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes 57 10 (2008 Oct) 2762-2767 [Electronic publication 2008 Jul 15]
29. Sipilä K., Koivistoinen T., Moilanen L., Nieminen T., Reunanen A., Jula A., Salomaa V., Kaaja R., Kööbi T., Kukkonen-Harjula K., Majahalme S., and Kähönen M. Metabolic syndrome and arterial stiffness: the Health 2000 Survey. Metabolism 56 3 (Mar 2007) 320-326
30. Lim P., Collet J.P., Moutereau S., Guigui N., Mitchell-Heggs L., Loric S., Bernard M., Benhamed S., Montalescot G., Dubois Rande J.L., and Gue'ret P. Fetuin-A is an independent predictor of death after ST-elevation myocardial infarction. Clin Chem 53 (2007) 10,1835-10,1840
31. Mori K., Emoto M., Araki T., Yokoyama H., Teramura M., Lee E., Motoyama K., Koyama H., Shoji T., Inaba M., and Nishizawa Y. Association of serum fetuin-A with carotid arterial stiffness. Clin Endocrinol (Oxf) 66 (2007) 246-250
32. Rosano G.M., and Panina G. Oestrogens and the heart. Therapie 54 3 (May-Jun 1999) 381-385
33. Willum-Hansen T., Staessen J.A., Torp-Pedersen C., Rasmussen S., Thijs L., Ibsen H., and Jeppesen J. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 113 5 (Feb 7 2006) 664-670
34. Cozzolino M., Biondi M.L., Galassi A., Gallieni M., Melzi d'Eril G.V., and Brancaccio D. Gene polymorphism and serum alpha-2-Heremans-Schmid levels in Italian haemodialysis patients. Am J Nephrol 27 (2007) 639-642